. Author manuscript; available in PMC: 2020 Nov 1.

Published in final edited form as: Mol Cancer Ther. 2020 Mar 10;19(5):1148–1156. doi: 10.1158/1535-7163.MCT-19-1117

Table 2.

Summary of all grades (2–5) toxicities observed in > 10% of patients that were considered possibly, probably, or definitely related to study related intervention.

Treatment related (possible, probable, or definite) toxicities that occurred in > 10% of patients
Toxicity	Cohort 1			Cohort 2			Cohort 3				Cohort 4			Cohort 5
Irinotecan	150 mg/m²			150 mg/m²			180 mg/m²				150 mg/m²			180 mg/m²
Reovirus	1 X 10¹⁰ TCID₅₀			3 X 10¹⁰ TCID₅₀			3 X 10¹⁰ TCID₅₀				3 X 10¹⁰ TCID₅₀			3 X 10¹⁰ TCID₅₀
Bevacizumab	None			None			None				5 mg/kg			5 mg/kg
n	3			12			6				7			8
Grade	2	3	4	2	3	4	2	3	4	5	2	3	4	2	3	4

Myelosuppression
Neutropenia		1			5	1		1	3			3	1	3	3
Anemia				3	1		1	2	1			2			3
Thrombocytopenia				1	1			3	1^**					1
Infection				2	1					1^**				1
GI Symptoms
Diarrhea				4			2				1	1		3	2
Constipation	1			1										2
Nausea	1			2				1			2
Vomiting				2				1				1	2	1
Stomatitis^#					1									1
Anorexia	1			2							2			1
Dehydration								1
Flu like symptoms
Fatigue	2			5	2		3				3			3	2
Pyrexia				1			1							1
Dehydration								1
Musculoskeletal^$					2						4			1
Generalized
Dizziness				3							2
Insomnia				4			2				1			2
Dyspnea								1							1
DVT				1							1				2
HTN				1			1				1			1	3
Epistaxis				1					1		1			3	1
Proteinuria											2			3	2

includes oropharyngeal pain, mucositis

includes arthralgias, back pain, myalgias, extremity pain, headaches

^**

Dose limiting toxicity